Shining light on vitamin D trials in chronic kidney disease

Kidney International

Volumn 83, Issue 2, 2013, Pages 198-200

  Nigwekar, Sagar U ^a,b   Thadhani, Ravi I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; ERGOCALCIFEROL; GLUCOSE; INSULIN; PARICALCITOL; PLACEBO; VITAMIN D; VITAMIN D RECEPTOR;

CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL DESIGN; GLUCOSE METABOLISM; HUMAN; INSULIN SENSITIVITY; INTENTION TO TREAT ANALYSIS; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SYNDROME DELINEATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84873399354     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.415     Document Type: Note

References (12)

1. Levey AS, Atkins R, Coresh J et al. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72: 247-259.
2. Samuels JA, Molony DA. Randomized controlled trials in nephrology: state of the evidence and critiquing the evidence. Adv Chronic Kidney Dis 2012; 19: 40-46.
3. de Boer IH, Sachs M, Hoofnagle AN et al. Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. Kidney Int 2012; 83: 323-330.
4. Thomas G, Sehgal AR, Kashyap SR et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6: 2364-2373.
5. Siew ED, Ikizler TA. Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Semin Dial 2010; 23: 378-382.
6. Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 2012; 7: 358-365.
7. Wolden-Kirk H, Overbergh L, Christesen HT et al. Vitamin D and diabetes: its importance for beta cell and immune function. Mol Cell Endocrinol 2011; 347: 106-120.
8. Kautzky-Willer A, Pacini G, Barnas U et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47: 200-206.
9. Mak RH. 1, 25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53: 1353-1357.
10. Slatopolsky E, Finch J, Ritter C et al. A new analog of calcitriol, 19-nor-1, 25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852-860.
11. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684.
12. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 1995; 48: 23-40.